Living Cell Technologies Group 1 Patients Successfully Treated in Parkinson's Trial
05 October 2016 - 12:58PM
Business Wire
Living Cell Technologies Limited has completed treatment of all
six patients in group 1 of the Phase IIb clinical trial of NTCELL®
for Parkinson’s disease, at Auckland City Hospital. Four patients
had 40 NTCELL microcapsules implanted into the putamen on each side
of their brain, and two patients had sham surgery with no NTCELL
implanted. To date there are no safety issues in any of the six
patients.
The company is blind to the results until 26 weeks after
completion of the trial, at which point the patients who received
the placebo will receive the optimal dose of NTCELL.
The next step is the Data Safety Monitoring Board reviewing the
patients’ results and giving approval to treat the six patients in
group 2 with the next dose of NTCELL (80 microcapsules implanted
into the putamen on each side of their brain).
Principal Investigator Dr Barry Snow presented data from the
earlier Phase I/IIa clinical trial to prospective patients and
their partners and supporters at meetings organised by Parkinson’s
New Zealand. These meetings were oversubscribed and have assisted
patient recruitment for the clinical trial.
Auckland City Hospital has invested in additional equipment and
arranged extra surgical sessions dedicated to treating multiple
patients in the clinical trial. These measures will accelerate
trial progress.
The company plans to complete group 2 by the end of 2016 and
group 3 by the end of February 2017.
The Phase IIb trial aims to confirm the most effective dose of
NTCELL, define any placebo component of the response and further
identify the initial target Parkinson’s disease patient sub group.
If the trial is successful, the company will apply for provisional
consent to treat paying patients in New Zealand in Q4 2017.
For further information: www.lctglobal.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161004006702/en/
At the Company:Living Cell Technologies LimitedKen
Taylor, +64 9 276 2690Chief ExecutiveMobile: +64 21 796
000ktaylor@lctglobal.comorMedia Contact:Botica Butler Raudon
PartnersRachael Joel, +64 9 303 3862Mobile: +64 21 403
504rachaelj@botica.co.nz
Living Cell Technologies (ASX:LCT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Living Cell Technologies (ASX:LCT)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Living Cell Technologies Limited (Australian Stock Exchange): 0 recent articles
More Liv Cell Fpo News Articles